Greg Mattingly Usa parish St. Charles abuse treating adhd Manufacturing Greg Mattingly Usa parish St. Charles

FDA Approves Nonstimulant ADHD Medication Qelbree for Adult Use

Reading now: 181

May 3, 2022The first nonstimulant ADHD medication for adults introduced in two decades, Qelbree was approved last week by the U.S.

Food & Drug Administration (FDA) for use in patients aged 18 to 65. Qelbree (viloxazine) is an extended-release capsule taken once a day that showed no evidence of abuse potential in clinical studies.

FDA approval followed review of a randomized, double-blind, placebo-controlled Phase III study of Qelbree in adults with ADHD that showed “efficacy and symptom improvement” early in treatment, according to the drug manufacturer Supernus Pharmaceuticals. (Qelbree received FDA approval for the treatment of ADHD in children ages 6 to 17 in April 2021.)“Until today, nonstimulant ADHD options for adults have been very limited,” said Greg Mattingly, M.D., founding partner of St.

The website is an aggregator of articles from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the article if you find it unreliable.

Related articles